Intra-Cellular Therapies to Participate in Investor Conferences
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI) is a biopharmaceutical company dedicated to creating and marketing treatments for disorders of the central nervous system (CNS). The company is gearing up to showcase its advancements at three major investor conferences, providing a valuable opportunity for both shareholders and prospective investors to gain insight into its pioneering work in the biopharmaceutical arena.
Conference Details
Dr. Sharon Mates, the Chief Executive Officer and Chairman of Intra-Cellular Therapies, will be leading presentations at the following conferences:
Morgan Stanley 22nd Annual Global Healthcare Conference
The first event on the agenda is the Morgan Stanley 22nd Annual Global Healthcare Conference, set for September 4. Dr. Mates is scheduled to speak at 10:00 a.m. ET, where she will share valuable insights into the company’s recent progress and future plans.
Baird’s 2024 Global Healthcare Conference
Next on the schedule is Baird’s 2024 Global Healthcare Conference, which will take place on September 11 at 11:25 a.m. ET. This conference aims to foster discussions about innovative healthcare solutions and advancements in pharmaceuticals.
2024 Cantor Global Healthcare Conference
Finally, Dr. Mates will present at the 2024 Cantor Global Healthcare Conference on September 18 at 10:55 a.m. ET. Each of these presentations will highlight Intra-Cellular Therapies’ dedication to improving mental health and advancing neurological research.
Accessing the Presentations
For those who cannot attend in person, a live and archived webcast of the presentations will be available. Interested viewers can find more information in the 'Events & Presentations' section of the Investors area on the company's official website. It is advisable to log in about 5-10 minutes before the event to ensure a smooth registration process and to address any necessary software installations for viewing.
Company Overview
Intra-Cellular Therapies is at the cutting edge of neurological research, utilizing Nobel prize-winning science to explore the cellular mechanisms behind neurological and psychiatric disorders. The company is committed to developing treatments for complex psychiatric and neurologic diseases, establishing itself as a leader in the biopharmaceutical industry. Its innovative intracellular approach is crucial for creating therapeutics aimed at enhancing the quality of life for those affected by these conditions.
Contact Information
For additional inquiries or information regarding presentations or the company’s strategic initiatives, interested individuals can contact:
Intra-Cellular Therapies, Inc.
Juan Sanchez, M.D.
Vice President, Corporate Communications and Investor Relations
646-440-9333
For media inquiries, please reach out to Burns McClellan, Inc.
Cameron Radinovic
646-930-4406
Frequently Asked Questions
What is Intra-Cellular Therapies known for?
Intra-Cellular Therapies is recognized for its development of innovative therapeutics targeting central nervous system disorders.
Who will be presenting at the upcoming conferences?
Dr. Sharon Mates, the CEO and Chairman of Intra-Cellular Therapies, will be the presenter at these conferences.
When are the upcoming investor conferences?
The investor conferences are scheduled for September 4, September 11, and September 18.
How can the presentations be accessed?
The presentations will be accessible through a live and archived webcast available on the company's official website in the Investors section.
What is the focus of Intra-Cellular Therapies?
Intra-Cellular Therapies focuses on developing treatments for psychiatric and neurologic diseases, based on a cellular understanding of the human body.